On July 21, 1978, the FDA published a final rule in the Federal Register (43 FR 31508) setting out the CGMP requirements for medical devices under Section 520(f) of the FD&C Act. These regulations came into force on December 18, 1978 and are codified in Part 820. What it covers: 21 CFR Part 820 Subpart C covers design controls. Design controls are procedures that ensure that devices are designed in accordance with their requirements. Definitions of key terms related to quality management systems can be found in the current § 820.3 and section 3 of ISO 13485. We reviewed the definitions in ISO 13485 to determine their suitability for FDA purposes. We note that most of the definitions in Article 3 are acceptable; Therefore, unless otherwise stated in this section, we are not proposing any changes to the terms and definitions in clause 3 and propose to delete the corresponding terms and definitions from the current Part 820. However, in some cases, the current definitions in §820.3 include terms that ISO 13485 does not include and vice versa. In addition, some definitions in ISO 13485 do not comply with the requirements of the FD&C Act and its implementing regulations. Home Page printed 10125 As mentioned above, the FDA proposes to incorporate the International Standard, ISO 13485:2016 Medical devices – Quality management systems – Requirements for regulatory purposes, third edition 2016-03-01, by reference. ISO 13485 provides a comprehensive approach to establishing a quality management system for medical devices.
When this proposed rule is completed, it will provide most CGMP requests for devices. We note that the ISO 9000 definitions apply to ISO 13485; However, to the extent that there is a conflict between ISO 9000 and the FD&C Act and its implementing regulations, the FD&C Act and its implementing provisions would prevail. We also propose to clarify that section 7.3 Design and development applies only to manufacturers of Class I devices listed in this provision, in addition to all manufacturers of Class II and III devices. This maintains the scope of the current § 820.30(a). We do not propose to modify equipment subject to these requirements and only revise this provision to reflect the position of similar requirements in ISO 13485. We also note that this is consistent with Section 1 of ISO 13485, which recognizes that there may be exemptions to the design and development requirement by the regulator and requires the manufacturer to document this in its justification for the exclusion. Process validation. ISO 13485 uses the term „process validation” and does not contain its own definition of the term. We propose to clarify the term „process validation” as used in ISO 13485 to refer to „process validation” as defined in Part 820.
We retain the definition of process validation (§ 820.3(z)(1)) because ISO 13485 does not define „process validation”, but the use is the same as that intended for process validation under Part 820. This will also allow alignment between ISO 13485 and other requirements of the FD&C Act and its implementing regulations. In 2012, the FDA developed a voluntary pilot program to submit audit reports that are no longer operational and in which the FDA accepted a manufacturer`s ISO 13485:2003 audit report (Ref. 8). Through this program, the FDA has established the feasibility and use of ISO 13485 audit reports instead of routine FDA inspections that cover the requirements of the Quality Assurance Regulation. In addition, the FDA participates in the International Medical Device Regulators Forum (IMDRF), a voluntary group of medical device regulators from around the world Start Printed page 10122 focused on regulatory harmonization and convergence (Ref. 9). IMDRF developed MDSAP in 2012.
Under MDSAP, audits are carried out based on the basic requirements of ISO 13485 with additional country-specific requirements. In deciding whether or not to participate in MDSAP and what FDA-specific regulations were required for the United States, the FDA conducted a thorough review and comparison of ISO 13485 and Part 820 and concluded that very few FDA-specific requirements should be added to this audit template. which not only shows the similarities between the current Part 820 and ISO 13485. but the overall QMS approach of ISO 13485. This allowed the FDA to participate in the MDSAP and accept some MDSAP audits as a substitute for its own routine monitoring of device quality systems (Ref. 5). Subsection § 820.180 specifies the general requirements: According to proposed § 820.35 (c), in addition to the requirements of sections 7.5.1, 7.5.8 and 7.5.9 of ISO 13485, the UDI for each medical device or batch of medical devices must be registered. The estimated registration effort associated with UDI is included in the estimate of „Registration Control (Project § 820.35)” in Table 4. Common mistake: Some medical device companies provide instructions for service, but don`t do enough to verify that the device meets specifications after maintenance.
To ensure that specifications are met, define your requirements, specifications and maintenance procedures. Keep records to confirm that maintenance has been performed correctly and has indeed been verified as effective. (a) complaint files. In addition to section 8.2.2 of ISO 13485, Handling of complaints, the manufacturer shall record at least the following information for complaints that are to be reported to the FDA in accordance with Part 803 of this chapter, complaints that a manufacturer detects shall be investigated, and complaints that the manufacturer has reviewed independently of these requirements: Current § 820.5 requires manufacturers to establish and maintain a quality management system that meets the requirements of Part 820. We propose to move this requirement to the codified requirements and revise this provision to require that a quality management system that complies with ISO 13485 as amended by proposed Part 820 be documented. These requirements will serve as minimum requirements for the implementation of a QMS that complies with the final version of this proposed rule. When ISO 13485 refers to evidence documentation, we generally recommend that manufacturers record quantitative data, as this information helps manufacturers monitor the performance of their processes and the effectiveness of their process controls. The QMR for equipment refers to the requirements of Part 820 of this chapter.
Description: The FDA proposes to revise its CGMP requirements for devices in accordance with the QS Regulation codified in Part 820. Through this rule-making proposal, the FDA intends to converge its requirements with the QMS requirements of other regulatory agencies. The FDA is trying to achieve this primarily by incorporating ISO 13485. Once completed, this rule would align QMS requirements for instruments with the requirements of other regulators. The FDA has always recognized the benefits of harmonization with other regulators and has taken a number of steps over time to promote consistency with its regulatory counterparts. As part of these activities, the FDA proposes to revise its CGMP requirements for devices under the QS Regulation codified in Part 820 (21 CFR Part 820). Through this rule-making proposal, the FDA intends to merge its requirements with the quality management system requirements of other regulatory agencies. The FDA seeks to achieve this goal primarily by including the 2016 edition of the International Organization for Standardization (ISO) 13485 (ISO 13485). Once finalized, this rule would harmonize the requirements of the product quality management system with those of other regulatory bodies. This harmonisation should enable patients to access the necessary products more effectively, which should improve the quality of life of consumers. (c) Design and development. Manufacturers of Class II, Class III and Class I devices listed below shall comply with the requirements of clause 7.3 design and development and its subsections of ISO 13485.
Class I devices are as follows: (1) For clause 7.5.8 of ISO 13485, identification, the manufacturer shall document a system for assigning a unique device identification to the medical device in accordance with the requirements of Part 830. Current § 820.1(b) states that in the event of a conflict between the provisions of Part 820 and a specifically applicable provision of Chapter I of Title 21 of the CFR, the provisions that apply specifically to the product in question will replace other generally applicable requirements. A reader might interpret this provision in such a way that the specifically applicable regulations render the rest of the Part 820 rule completely unenforceable. The purpose of the proposed amendment is to clarify that the generally applicable rules of Part 820 apply, unless they otherwise conflict with the specifically applicable regulations.